Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aliskiren
Drug ID BADD_D00073
Description Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.[L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]
Indications and Usage For the treatment of hypertension, to lower blood pressure.
Marketing Status Prescription
ATC Code C09XA02
DrugBank ID DB09026
KEGG ID D03208
MeSH ID C446481
PubChem ID 5493444
TTD Drug ID D03SVX
NDC Product Code 49884-425; 49884-424
Synonyms aliskiren | rasilez | Tekturna | CGP 060536B | CGP060536B | CGP-060536B | 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate | SPP100
Chemical Information
Molecular Formula C30H53N3O6
CAS Registry Number 173334-57-1
SMILES CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscular weakness17.05.03.005; 15.05.06.0010.002793%
Musculoskeletal pain15.03.04.007--
Myocardial infarction24.04.04.009; 02.02.02.0070.004189%
Myocardial ischaemia24.04.04.010; 02.02.02.0080.002793%Not Available
Myositis15.05.01.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.001--Not Available
Oedema14.05.06.010; 08.01.07.0060.004189%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.006982%
Orthopnoea22.02.01.020; 02.01.03.0060.002793%Not Available
Pain in extremity15.03.04.0100.005586%
Palpitations02.01.02.003--
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Pneumonia11.01.09.003; 22.07.01.0030.006982%Not Available
Pneumonia aspiration22.01.01.0050.000729%Not Available
Proteinuria20.02.01.0110.002793%
Pruritus23.03.12.001--
Pulmonary oedema22.01.03.003; 02.05.02.0030.001093%
Pyrexia08.05.02.0030.006982%
Rales22.02.04.0040.004189%Not Available
Rash23.03.13.001--Not Available
Renal cancer20.01.04.002; 16.08.02.0010.000729%Not Available
Renal failure20.01.03.0050.003643%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001093%
Retinal artery embolism24.01.07.004; 06.10.01.0060.000729%Not Available
Rhabdomyolysis15.05.05.002--
Rhinitis22.07.03.006; 11.01.13.004--
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages